Core B Chemistry/Biochemistry/ Pharmacology Component

$234,820P01FY2016DANIH

Northeastern University, Boston MA

Investigators

Linked publications & trials

Paper 39109814 Paper 38936657 Paper 38850666 Paper 38826401 Paper 38328157 Paper 38059442 Paper 38052772 Paper 37646476 Paper 37286073 Paper 37212036 Paper 37164640 Paper 36613692 Paper 36564457 Paper 36417942 Paper 36248648 Paper 36179954 Paper 35787179 Paper 35560902 Paper 35288510 Paper 35288509 Paper 35001054 Paper 34935460 Paper 33491188 Paper 33101030 Paper 32004463 Paper 31756109 Paper 31641018 Paper 30739035 Paper 30639103 Paper 30504240 Paper 30275151 Paper 30120413 Paper 29669714 Paper 29440756 Paper 29192123 Paper 28823711 Paper 28750807 Paper 28678776 Paper 28660254 Paper 28608535 Paper 28592614 Paper 28516479 Paper 27927913 Paper 27890725 Paper 27773824 Paper 27768894 Paper 27367336 Paper 27264437 Paper 27194477 Paper 27178246 Paper 26888056 Paper 26803499 Paper 26558620 Paper 26555264 Paper 26529344 Paper 26397760 Paper 26387676 Paper 26260601 Paper 26134495 Paper 25978068 Paper 25960577 Paper 25958314 Paper 25904556 Paper 25801236 Paper 25772338 Paper 25760146 Paper 25701254 Paper 25648895 Paper 25572435 Paper 25535367 Paper 25485182 Paper 25470070 Paper 25392487 Paper 25384424 Paper 25275313 Paper 25255720 Paper 24900848 Paper 24866555 Paper 24853387 Paper 24742127 Paper 24707904 Paper 24319298 Paper 24286207 Paper 24052669 Paper 24005529 Paper 23935221 Paper 23795559 Paper 23621789 Paper 23553709 Paper 23427192 Paper 23426954 Paper 23083016 Paper 23055515 Paper 22998838 Paper 22952796 Paper 22921769 Paper 22796181 Paper 22749867 Paper 22662211 Paper 22579668

Abstract

RESEARCH & RELATED - OTHER PROJECT INFORMATION - PROJECT SUMMARY/ABSTRACT This Core B facility will serve as a technical and scientific support unit for the three projects (1, 2, 3) of this Program Project. Its major goals involve: (1) the re-synthesis and scale-up of compounds in sufficient quantifies to address the in vitro and in vivo needs of the research laboratories involved in the four projects; all compounds will be evaluated in silico for their druggability properties as well (2) the testing of all new ligands for their affinities for the CB1 and CB2 cannabinoid receptors; (3) the testing of ligands for their abilities to bind irreversibly to CB1 and CB2; (4) the testing of a class of ligands for their abilities to act as substrates or inhibitors for the endocannabinoid deactivating enzymes, FAAH and MGL; (5) determining the functional properties of successful ligands initially in the cAMP assay; (6) determining the biochemical stabilities of ligands using liver microsomal preparations; (7) evaluation of a select group of novel ligands in mice for bioavailability and their ability to cross the blood brain barrier; and (8) evaluation of CB1 antagonists in vivo (mice) for their ability to antagonize the effects of an agonist. Compounds produced under the auspices of Core B will also be made available to other laboratories identified in this program project whose collaboration is at no cost to the grant.

View original record on NIH RePORTER →